The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...

In a report released today, Mathieu Chevrier from Citi maintained a Hold rating on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs ...

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing ...

Three S&P/ASX 200 Index (ASX: XJO) healthcare stocks are well placed to outperform in 2025. Here’s what you need to know.

ResMed, Inc. holds a major position as designer, manufacturer, as well as a distributor in the worldwide market for generators, masks, and related accessories for the treatment of sleep-disordered ...

Read more. ResMed CPAP masks subject to Class I recall over magnetic interference issue Six reported injuries related to magnets on the headgear of CPAP machines by ResMed Ltd. have resulted in a ...

Based in San Diego, California, ResMed Inc. (RMD ... the company primarily provides generators, masks, and related accessories for the treatment of sleep-disordered breathing (SDB) and other ...

The GARP strategy helps investors gain exposure to stocks that have impressive prospects and are trading at a discount. OUT, ...